507 related articles for article (PubMed ID: 31563344)
1. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
5. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Martin-Loeches I; Timsit JF; Kollef MH; Wunderink RG; Shime N; Nováček M; Kivistik Ü; Réa-Neto Á; Bruno CJ; Huntington JA; Lin G; Jensen EH; Motyl M; Yu B; Gates D; Butterton JR; Rhee EG
J Antimicrob Chemother; 2022 Mar; 77(4):1166-1177. PubMed ID: 35022730
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Martin-Loeches I; Shorr AF; Wunderink RG; Kollef MH; Timsit JF; Yu B; Huntington JA; Jensen E; Bruno CJ
Ann Intensive Care; 2023 Feb; 13(1):8. PubMed ID: 36773112
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Paterson DL; Bassetti M; Motyl M; Johnson MG; Castanheira M; Jensen EH; Huntington JA; Yu B; Wolf DJ; Bruno CJ
J Antimicrob Chemother; 2022 Aug; 77(9):2522-2531. PubMed ID: 35781341
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Huntington JA; Yu B; Li L; Jensen E; Bruno C; Boakye M; Zhang Z; Gao W; Feng HP; Rhee E
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988827
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.
Lodise T; Yang J; Puzniak LA; Dillon R; Kollef M
Infect Dis Ther; 2020 Dec; 9(4):953-966. PubMed ID: 32996064
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan.
Takaya R; Mori N; Saito E; Ohde S
BMC Health Serv Res; 2024 Mar; 24(1):389. PubMed ID: 38549158
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Shorr AF; Bruno CJ; Zhang Z; Jensen E; Gao W; Feng HP; Huntington JA; Yu B; Rhee EG; De Anda C; Basu S; Kollef MH
Crit Care; 2021 Oct; 25(1):354. PubMed ID: 34600585
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
Martin-Loeches I; Bruno CJ; DeRyke CA
Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
19. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP
Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]